Skip to Main Content

National Coverage Determination (NCD) for Anti-Inhibitor Coagulant Complex (AICC) (110.3)

Select the ’Print Record’, ‘Add to Basket’ or ‘Email Record’ buttons to print the record, to add it to your basket or to email the record.
  • Expand All
  • Collapse All
Publication Number

100-3

Manual Section Number

110.3

Manual Section Title

Anti-Inhibitor Coagulant Complex (AICC)


Version Number

1

Effective Date of this Version

This is a longstanding national coverage determination. The effective date of this version has not been posted.


Benefit Category
Blood Clotting Factors for Hemophilia Patients
Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Indications and Limitations of Coverage

Anti-inhibitor coagulant complex, AICC, is a drug used to treat hemophilia in patients with factor VIII inhibitor antibodies. AICC has been shown to be safe and effective and has Medicare coverage when furnished to patients with hemophilia A and inhibitor antibodies to factor VIII who have major bleeding episodes and who fail to respond to other, less expensive therapies.


20